2022
DOI: 10.1016/j.bioorg.2022.105983
|View full text |Cite
|
Sign up to set email alerts
|

Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer’s disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 73 publications
0
2
0
Order By: Relevance
“…28). 213 Because levels of the neurotransmitter acetylcholine and O-GlcNAcase are associated with hyperphosphorylation of tau protein, both O-GlcNAcase and cholinesterase are potentially effective targets for the treatment of Alzheimer's disease. This inhibitor was designed to contain the selenazoline core because it was anticipated that the Se-containing bicyclic structure could better adapt within the key enzyme regions than the isosteric thiazoline structure.…”
Section: Glycosidase Inhibitorsmentioning
confidence: 99%
“…28). 213 Because levels of the neurotransmitter acetylcholine and O-GlcNAcase are associated with hyperphosphorylation of tau protein, both O-GlcNAcase and cholinesterase are potentially effective targets for the treatment of Alzheimer's disease. This inhibitor was designed to contain the selenazoline core because it was anticipated that the Se-containing bicyclic structure could better adapt within the key enzyme regions than the isosteric thiazoline structure.…”
Section: Glycosidase Inhibitorsmentioning
confidence: 99%
“…Carbohydrate derivatives are an important class of bioactive compounds with a high density of functional groups [ 1 ]. Carbohydrates annulated with heterocycles demonstrate interesting biological properties, including fructose transporter protein GLUT5 inhibition and the selective inhibition of glycoside hydrolase O-GlcNAcase (OGA) or the dual inhibition of OGA and cholinesterases, which are relevant for new therapeutic candidates [ 2 , 3 , 4 ].…”
Section: Introductionmentioning
confidence: 99%